Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AOC 1044 in Healthy Volunteers and Duchenne Muscular Dystrophy
NCT05670730Phase 2Completed
- Sponsor
- Avidity Biosciences
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Antisense DNA, Antibody Conjugates, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delpacibart zotadirsen in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Avidity Biosciences. Primary endpoint: Incidence of treatment-emergent adverse events at Day 169. Started Nov 2022; status: completed.
02
Drugs
delpacibart zotadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05670730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670730.